Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a strong sell rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

Several other brokerages have also recently issued reports on TVRD. BTIG Research lowered their price target on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Lucid Cap Mkts upgraded Tvardi Therapeutics to a “strong-buy” rating in a report on Tuesday, September 8th. UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. Finally, Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Tvardi Therapeutics Stock Down 2.1%

Shares of NASDAQ TVRD opened at $1.83 on Friday. The stock has a market cap of $24.41 million, a P/E ratio of -0.66 and a beta of 0.32. The firm’s 50-day simple moving average is $2.26 and its 200 day simple moving average is $2.89. Tvardi Therapeutics has a fifty-two week low of $1.50 and a fifty-two week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, sell-side analysts anticipate that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tvardi Therapeutics

Large investors have recently made changes to their positions in the company. Susquehanna International Group LLP purchased a new position in Tvardi Therapeutics during the 2nd quarter worth approximately $63,000. BlackRock Inc. acquired a new stake in Tvardi Therapeutics during the 2nd quarter valued at $181,000. GSA Capital Partners LLP purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at $34,000. Finally, Duncan Williams Asset Management LLC lifted its holdings in shares of Tvardi Therapeutics by 266.6% in the fourth quarter. Duncan Williams Asset Management LLC now owns 80,771 shares of the company’s stock valued at $347,000 after purchasing an additional 58,741 shares in the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.